Kymera Therapeutics (KYMR) director discloses fund-held stock sales

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. reported insider activity showing that a director, filing individually, completed multiple sales of Kymera common stock on December 10–12, 2025 through affiliated investment funds. The transactions involved several blocks of common stock sold at weighted average prices including $88.64, $89.25, $90.14, $92.41, $93.20, $91.23 and $91.04 per share, with underlying trade prices ranging from $88.00 to about $93.69 per share as described in the footnotes.

After these sales, Atlas Venture Fund X, L.P. held 3,974,481 Kymera shares and Atlas Venture Opportunity Fund I, L.P. held 685,393 shares, reported as indirectly beneficially owned by the director through general partner entities. The director disclaims beneficial ownership of these fund-held securities except to the extent of any pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Booth Bruce

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

200 ARSENAL YARDS BLVD., SUITE 230

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/10/2025		S		31,459	D	$88.64(1)	4,141,757	I	See footnote(2)
Common Stock	12/10/2025		S		17,825	D	$89.25(3)	4,123,932	I	See footnote(2)
Common Stock	12/10/2025		S		10,545	D	$90.14(4)	4,113,387	I	See footnote(2)
Common Stock	12/10/2025		S		47,349	D	$92.41(5)	4,066,038	I	See footnote(2)
Common Stock	12/10/2025		S		85,862	D	$93.2(6)	3,980,176	I	See footnote(2)
Common Stock	12/10/2025		S		5,979	D	$88.64(1)	717,267	I	See footnote(7)
Common Stock	12/10/2025		S		3,391	D	$89.25(3)	713,876	I	See footnote(7)
Common Stock	12/10/2025		S		2,001	D	$90.14(4)	711,875	I	See footnote(7)
Common Stock	12/10/2025		S		9,060	D	$92.41(5)	702,815	I	See footnote(7)
Common Stock	12/10/2025		S		16,338	D	$93.2(6)	686,477	I	See footnote(7)
Common Stock	12/11/2025		S		5,125	D	$91.23(8)	3,975,051	I	See footnote(2)
Common Stock	12/11/2025		S		976	D	$91.23(8)	685,501	I	See footnote(7)
Common Stock	12/12/2025		S		570	D	$91.04(9)	3,974,481	I	See footnote(2)
Common Stock	12/12/2025		S		108	D	$91.04(9)	685,393	I	See footnote(7)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.00 to $88.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (1), (3), (4), (5), (6), (8) and (9).

2. These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend of his pecuniary interest therein, if any.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.00 to $89.71 inclusive.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.55 inclusive.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.00 to $92.9969 inclusive.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.00 to $93.6935 inclusive.

7. The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.

8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.00 to $91.54 inclusive.

9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.00 to $91.33 inclusive.

	/s/ Ommer Chohan, Attorney-in-Fact	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider stock activity did Kymera Therapeutics (KYMR) disclose in this Form 4?

The filing shows that a Kymera Therapeutics, Inc. director reported multiple sales of Kymera common stock on December 10, 11 and 12, 2025. The sales were executed in several tranches at different weighted average prices, as detailed in Table I of the report.

How many Kymera Therapeutics shares do the Atlas Venture funds hold after the reported transactions?

Following the reported sales, Atlas Venture Fund X, L.P. held 3,974,481 shares of Kymera common stock, and Atlas Venture Opportunity Fund I, L.P. held 685,393 shares. These positions are reported as indirectly beneficially owned by the director through the funds’ general partner entities.

At what prices were the Kymera Therapeutics (KYMR) shares sold in these transactions?

The reported weighted average sale prices per share include $88.64, $89.25, $90.14, $92.41, $93.20, $91.23 and $91.04. Footnotes explain that each figure reflects multiple trades within price ranges from $88.00 up to approximately $93.69 per share.

Who actually holds the Kymera shares reported in this Form 4 filing?

The shares are held directly by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P.. The filing explains that their respective general partners are Atlas Venture Associates X, L.P. and Atlas Venture Associates Opportunity I, L.P., whose general partners are LLC entities in which the reporting director is a member.

What does the director say about beneficial ownership of the Kymera shares held by the funds?

The director disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X and Atlas Venture Opportunity Fund I, except to the extent of any pecuniary interest. This clarification appears in the explanatory footnotes to the Form 4.

What is meant by a weighted average price in the Kymera (KYMR) Form 4 footnotes?

The footnotes state that the reported prices in Column 4 are weighted average prices, meaning each figure represents multiple individual trades executed within a specified price range. The reporting person undertakes to provide full details of each trade price and share amount within those ranges upon request.

What is the reporting persons relationship to Kymera Therapeutics (KYMR)?

The filing identifies the reporting person as a Director of Kymera Therapeutics, Inc.. The form is filed for one reporting person, and the signature block shows it was signed by an attorney-in-fact on the reporting persons behalf.